p53 genetic abnormalities and P-glycoprotein expression in stump and primary gastric carcinomas

Hepato-Gastroenterology

Volumn 54, Issue 74, 2007, Pages 377-381

  Oliver, Israel ^a,c,e   Lacueva, Javier ^a,c   Barberá, Victor ^c   Caldés, Trinidad ^d   Teruel, Ana ^a   Costa, David ^a,c   Medrano, Justo ^a   Pérez Vázquez, Teresa ^a   Quesada, Paz ^d   Ferragut, José ^b   Calpena, Rafael ^a,c  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c Elche University Hospital   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e Campus de Sant Joan   (Spain)

Author keywords

Gastric stump carcinoma; Genetic abnormalities; Intestinal type primary gastric carcinoma; P glycoprotein; p53

Indexed keywords

BIOTIN; GLYCOPROTEIN P; PROTEIN P53; STREPTAVIDIN;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CELL MEMBRANE; CONTROLLED STUDY; EXON; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA;

BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DNA MUTATIONAL ANALYSIS; EXONS; GASTRIC STUMP; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34248184957     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Caygill CPJ, Hill MJ, Kirkham JS, et al: Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet 1986; 1(8487):929-931.
2. Tersmette AC, Goodman SN, Offerhaus GJA, et al: Multivariate analysis of the risk of gastric cancer after peptic ulcer surgery in an Amsterdam cohort of postgastrectomy patients. Am J Epidemiol 1991; 134:14-21.
3. Sobala GM, Pignatelli B, Schorah CJ, et al: Levels of nitrite, nitrate, N-nitroso compounds, ascorbic acid and total bile acids in gastric juice of patients with and without pre-cancerous conditions of the stomach. Carcinogenesis 1991; 12:193-198.
4. Offerhaus GJA, Stadt J van de, Huibregtse K, et al: The mucosa of the gastric remnant harboring malignancy. Histological findings in the biopsies of 504 asymptomatic patients 14-46 years after partial gastrectomy with the emphasis on non-malignant lesions. Cancer 1989; 64:698-703.
5. Offerhaus GJA, Stadt J van de, Samson G, et al: Cell proliferation kinetics in the gastric remnant. Eur J Cancer Res Clin Oncol 1985; 21:73-79.
6. Miwa K, Kamata T, Miyazaki I, et al: Kinetic changes and experimental carcinogenesis after Billtoth I and II gastrectomy. Br J Surg 1993; 80:893-896.
7. Correa P: The epidemiology of gastric cancer. World J Surg 1991; 15:228-234.
8. Lynch DAF, Mapstone NP, Clarke AMT, et al: Cell proliferation in the gastric corpus in Helicobacter pylori associated gastritis and after gastric resection. Gut 1995; 36:351-353.
9. Safatle-Ribeiro AV, Ribeiro TJ, Reynolds JC, et al: Morphologic histologic and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach. Cancer 1996; 78:2288-2299.
10. Baas IO, van Rees BP, Musler A, et al: Helicobacter pylori and Epstein-Barr virus infection and the p53 tumour suppressor pathway in gastric stump cancer compared with carcinoma in the non-operated stomach. J Clin Pathol 1998; 51:662-666.
11. zur Hansen A, van Rees BP, van Beek J, et al: Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol 2004; 57:487-491.
12. Sasako M, Maruyama K, Kinoshita T, et al: Surgical treatment of carcinoma of the gastric stump. Br J Surg 1991; 78:822-824.
13. Hartgrink HH, van de Velde CJH, Putter JJ, et al: Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004; 11:2069-2077.
14. Shimada K, Ajani JA: Adjuvant therapy for gastric carcinoma patients in the past 15 years. A review of western and oriental trials. Cancer 1999; 86:1657-1668.
15. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35:1059-1064.
16. Gonzalez Moreno S, Sugarbaker PH: Comprehensive management of resectable gastric cancer: Requirement for optimal clearance, containment and perioperative intraperitoneal chemotherapy. Rev Oncologia 2000; 3:129-140.
17. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach of the gastroesophageal junction. N England J Med 2001; 345(10):725-730.
18. Lenz HJ, Leichman G, Danenberg KD, et al: Thymidylate Synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1995; 14(1):176-182.
19. Lacueva FJ, Teruel A, Calpena R, et al: Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies. Histopathology 1998; 32:328-334.
20. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predictor response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16(1):309-316.
21. Renault B, van der Broek M, Fodde R, et al: Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 1993; 53:2614-2617.
22. Poremba C, Yandell DW, Huang Q, et al: Frequency and spectrum of p53 mutations in gastric cancer - a molecular genetic and immunohistochemical study. Virchows Arch 1995; 426:447-455.
23. Tolbert DM, Noffsinger AE, Miller MA, et al: p53 immunoreactivity and Single-Strand Conformational Polymorphism analysis often fail to predict p53 mutational status. Modern Pathol 1999; 12(1):54-60.
24. Tohdo H, Yokozaki H, Haruma K, et al: p53 gene mutations in gastric adenomas. Virchows Archiv B Cell Pathol 1993; 63:191-195.
25. Shiao Y, Rugge M, Correa P, et al: p53 alteration in gastric precancerous lesions. Am J Pathol 1994; 144:511-517.
26. Craanen ME, Block P, Dekker W, et al: Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995; 36:848-852.
27. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 1991; 351:453-456.
28. Hall PA, Lane DP: p53 in tumour pathology: can we trust immunohistochemistry? - Revisited J Pathol 1994; 172:1-4.
29. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-4878.
30. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-967.
31. Thottassery JV, Zambetti GP, Arimori K, et al: p53 dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 1997; 94:11037-11042.
32. Ogretmen B, Safa AR: Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997; 14:499-506.
33. Bellamy WT: P-glycoprotein and multidrug resistance. Annu Rev Pharmacol Toxicol 1996; 36:161-183.
34. Chin KV, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255:459-462.
35. Zastawny RL, Salvino R, Chen J, et al: The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 1993; 8:1529-1535.
36. Schneider J, Rubio MP, Barbazan MJ, et al: P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994; 86:850-855.
37. De Angelis P, Stokke T, Smedshammer L, et al: P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 1995; 72:307-311.
38. Linn SC, Honkoop AH, Hoekman K, et al: p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996; 74:63-68.
39. Ng IOL, Lam KY, Ng M, et al: Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma. Cancer 1998; 83:851-857.
40. Lacueva FJ, Calpena R, Medrano J, et al: Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53. Cancer 2000; 89:21-28.
41. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64:31-49.
42. Sobin LH, Wittekind Ch: In: Sobin LH, Wittekind Ch (Eds.). UICC TNM classification of malignant tumours. New York: Wille-Liss, 1997.
43. Barbera V, Martin M, Mariñoso L, et al: The 18q21 region in colorectal and pancreatic cancer: independent loss of DCC and DPC4 expression. Biochim Biophys Acta 2000; 1502:283-296.
44. Kohalmi SE, Kunz BA: Role of neighbouring bases and assessment of strand specificity in ethylmethanesulphonate and N-methyl-N′-nitro-N- nitrosoguanidine mutagenesis in the SUP4-o gene of Saccharomyces cerevisiae. J Mol Biol 1988; 204:561-568.
45. Nguyen T, Branson D, Crespi CL, et al: DNA damage and mutation in human cells exposed to nitric oxid in vitro. Proc Natl Acad Sci USA 1992; 89:3030-3034.
46. Shepherd T, Tolbert D, Benedetti J, et al: Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 2000; 118:1039-1044.
47. Joypaul BV, Hopwood D, Newman EL, et al: The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994; 69:943-946.
48. Gabbert HE, Møller W, Schneiders A, et al: The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995; 76:720-726.
49. Victorzon M, Nordling S, Haglund C, et al: Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 1996; 32A:215-220.